Osborne Partners Capital Management LLC raised its position in Amgen Inc. (NASDAQ:AMGN) by 0.6% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 16,932 shares of the medical research company’s stock after buying an additional 109 shares during the period. Osborne Partners Capital Management LLC’s holdings in Amgen were worth $2,778,000 as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of AMGN. First Republic Investment Management Inc. raised its position in shares of Amgen by 3.0% in the fourth quarter. First Republic Investment Management Inc. now owns 558,210 shares of the medical research company’s stock worth $81,616,000 after buying an additional 16,521 shares during the period. Third Avenue Management LLC increased its stake in Amgen by 56.6% in the fourth quarter. Third Avenue Management LLC now owns 210,262 shares of the medical research company’s stock worth $30,742,000 after buying an additional 76,036 shares during the period. Exchange Capital Management Inc. increased its stake in Amgen by 1.7% in the fourth quarter. Exchange Capital Management Inc. now owns 24,575 shares of the medical research company’s stock worth $3,593,000 after buying an additional 399 shares during the period. Private Asset Management Inc. increased its stake in Amgen by 117.8% in the first quarter. Private Asset Management Inc. now owns 3,591 shares of the medical research company’s stock worth $589,000 after buying an additional 1,942 shares during the period. Finally, Hamilton Point Investment Advisors LLC increased its stake in Amgen by 52.8% in the third quarter. Hamilton Point Investment Advisors LLC now owns 22,135 shares of the medical research company’s stock worth $3,692,000 after buying an additional 7,651 shares during the period. 78.84% of the stock is owned by institutional investors and hedge funds.

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Amgen Inc. (AMGN) traded down 0.76% during midday trading on Friday, reaching $172.50. 14,368,474 shares of the company’s stock were exchanged. The firm has a 50-day moving average price of $160.31 and a 200 day moving average price of $161.40. The company has a market cap of $126.86 billion, a price-to-earnings ratio of 16.38 and a beta of 1.37. Amgen Inc. has a 52 week low of $133.64 and a 52 week high of $184.21. Amgen also was the recipient of some unusual options trading activity on Wednesday. Stock traders acquired 2,287 call options on the company. This is an increase of 207% compared to the typical daily volume of 746 call options.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Wednesday, April 26th. The medical research company reported $3.15 earnings per share for the quarter, beating analysts’ consensus estimates of $3.00 by $0.15. Amgen had a net margin of 34.42% and a return on equity of 29.37%. The firm had revenue of $5.46 billion for the quarter, compared to analyst estimates of $5.60 billion. During the same period last year, the firm earned $2.90 earnings per share. The business’s quarterly revenue was down 1.1% compared to the same quarter last year. Analysts anticipate that Amgen Inc. will post $12.44 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This news story was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another publication, it was illegally copied and reposted in violation of United States & international trademark and copyright laws. The legal version of this news story can be viewed at https://www.thecerbatgem.com/2017/06/25/osborne-partners-capital-management-llc-has-2-78-million-position-in-amgen-inc-amgn-updated.html.

A number of research firms have weighed in on AMGN. Vetr downgraded Amgen from a “hold” rating to a “sell” rating and set a $174.10 target price for the company. in a research report on Monday, March 13th. Mizuho set a $195.00 price objective on Amgen and gave the company a “buy” rating in a research report on Friday, March 10th. Oppenheimer Holdings, Inc. reiterated an “outperform” rating and set a $189.00 price objective on shares of Amgen in a research report on Tuesday, March 14th. Piper Jaffray Companies reiterated an “overweight” rating and set a $193.00 price objective on shares of Amgen in a research report on Tuesday, March 14th. Finally, BMO Capital Markets reiterated an “outperform” rating and set a $212.00 price objective on shares of Amgen in a research report on Monday, March 6th. One analyst has rated the stock with a sell rating, twelve have given a hold rating, ten have assigned a buy rating and three have assigned a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $184.94.

In other Amgen news, SVP Cynthia M. Patton sold 2,922 shares of the firm’s stock in a transaction on Wednesday, May 24th. The shares were sold at an average price of $154.40, for a total value of $451,156.80. Following the transaction, the senior vice president now directly owns 24,214 shares of the company’s stock, valued at $3,738,641.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 0.20% of the stock is currently owned by company insiders.

About Amgen

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Receive News & Stock Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related stocks with our FREE daily email newsletter.